BSE · 530617
Sampre Nutritions Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹15 Cr with net profit ₹2 Cr — a 12.05% net margin, versus 8.93% the period before.
Shareholding
As of 2026-06-30
- Promoter14.04%
- Public85.96%
8,947 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 13.21× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ST-ASM · ASM 1. Trading may carry price bands, periodic call auction or higher margins.
- 52-week range spans 13.21× (₹5.44 to ₹71.85) — an unusually wide band.
Peer comparison
Food - Processing - Indian · ranked #63 of 110 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Varun Beverages Limited | ₹1,51,264 Cr | 173.33 | 7.73 | 15.51% | 13.68% |
| Hatsun Agro Product Ltd. | ₹19,727 Cr | 388.42 | 10.15 | 17.97% | 3.62% |
| Zydus Wellness Limited | ₹18,436 Cr | 113.84 | 3.17 | 3.98% | 5.01% |
| Bikaji Foods International Ltd. | ₹16,094 Cr | 285.27 | 10.01 | 16.07% | 8.8% |
| LT Foods Limited | ₹13,147 Cr | 21.02 | 2.91 | 13.83% | 5.71% |
| Avanti Feeds Limited | ₹12,898 Cr | 103.01 | 3.92 | 18.44% | 9.99% |
| Godrej Agrovet Limited | ₹10,779 Cr | 102.82 | 5.3 | 23.27% | 4.63% |
| Manorama Industries Ltd. | ₹10,389 Cr | 187.24 | 8.79 | 32.97% | 16.58% |
| KRBL Limited | ₹7,978 Cr | 12.31 | 1.37 | 11.16% | 10.63% |
| Orkla India Limited | ₹7,747 Cr | 104.73 | 2.82 | 10.39% | 11.39% |
| Sampre Nutritions Ltd.(this company) | ₹52 Cr | 17 | 0.48 | 2.87% | 8.26% |
AI analysis
AI-generated · google/gemini-2.5-flashSampre Nutritions Ltd. is listed with a market capitalization of Rs 67 Cr. The company reported a revenue of Rs 25.5 Cr, an EPS of 0.32, and a PE ratio of 22.06. The book value per share stands at Rs 11.3.
Positives
- +The company's debt-to-equity ratio is 0.3, indicating a relatively low level of debt.
- +Return on Equity (ROE) is 286.6%, suggesting efficient use of shareholder funds.
- +The company has no promoter share pledges as of June 30, 2026.
Negatives
- −The company reported a net loss of Rs 7.6723 Cr for the fiscal year ending March 2025, with an EPS of -5.43.
- −Promoter holding is relatively low at 14.0373% as of June 30, 2026.
- −The company is under ST-ASM surveillance, specifically at ASM 1.
- −The quarterly net profit significantly dropped from Rs 0.9 Cr in September 2025 to Rs 0.62 Cr in December 2025, and then rose to Rs 1.35 Cr in March 2026.
Financial performance
For the fiscal year ending March 2025, Sampre Nutritions Ltd. reported a revenue of Rs 25.4987 Cr, with a net loss of Rs 7.6723 Cr and an EPS of -5.43. More recently, in the quarter ending March 2026, the company recorded a revenue of Rs 15.1 Cr and a net profit of Rs 1.35 Cr.
Profitability & returns
The company's profit margin was 8.26%. Return on capital employed (ROCE) was 2.51%, while return on equity (ROE) was 286.6%. The company's EPS was 0.32.
Balance sheet
Sampre Nutritions Ltd. has a debt-to-equity ratio of 0.3. The book value per share is Rs 11.3. No dividend yield was reported.
Ownership & pledges
Public shareholding stands at 85.9627%. There were no shares pledged by the promoters.
Regulatory & surveillance
Sampre Nutritions Ltd. is under ST-ASM surveillance, specifically at ASM 1 stage, indicating enhanced monitoring by regulatory authorities due to factors such as price variation, volume variation, or other relevant parameters.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.